Details of the Entitlement Offer

On 3 September 2024, The Company announced its intention to undertake a pro rata accelerated non-renounceable entitlement offer (Entitlement Offer), to raise up to approximately A$10.0 million (before costs) at a price of A$0.038 (3.8 cents) per fully paid ordinary share (Share), on the basis of 1 new Share for every 1.82 Shares held as at 7.00pm (Sydney time) on the record date of Friday, 6 September 2024 (Record Date).

The offer price of A$0.038 per Share represents a 17.4% discount to the last closing Share price of $0.046 (as at 3 September 2024) and a 12.0% discount to the 5-day VWAP of $0.0432 (as at 3 September 2024). New Shares issued under the Entitlement Offer will rank equally with the existing Shares on issue.

The Entitlement Offer will provide eligible shareholders with the opportunity to take up new Shares proportional to their shareholding and mitigate the effect of dilution. Eligible shareholders who do not take up their entitlement under the Entitlement Offer in full or in part will not receive any value in respect to those entitlements not taken up.

Use of Funds

Funds raised from the Entitlement Offer are intended to be applied towards: (a) completion of the FebriDx Clinical Laboratory Improvement Amendment (CLIA) waiver trial in the US, product development, sales & marketing activities; (b) general working capital; and (c) costs of the Entitlement Offer.

Completion of the Institutional Entitlement Offer

The Institutional Entitlement Offer to raise approximately A$3.1 million via the issue of approximately 81.7 million new shares was well supported by eligible institutional shareholders as announced on 6 September 2024.

New shares were issued at a fixed price of A$0.038 (3.8 cents) per share and rank equally with existing shares from allotment.

Commencement of Retail Entitlement Offer

The Retail Entitlement Offer to raise approximately A$6.9 million via the issue of approximately 182.8 million new shares is now open and will close at 5.00pm (AEST) on Wednesday, 2 October 2024.

Eligible Retail Shareholders (defined below) who held shares in Lumos as at 7:00pm (AEST) on the Record Date of Friday, 6 September 2024 will be invited to participate in the Retail Entitlement Offer at the same offer price and offer ratio as the participants in the Institutional Entitlement Offer, being $0.038 (3.8 cents) per share and an offer ratio of 1 for 1.82.

Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer should carefully read the Retail Offer Booklet and accompanying personalised entitlement form below.

Offer Timetable

FAQs

1. Why is Lumos conducting this Entitlement Offer?
   The proceeds from the Entitlement Offer will be allocated towards completing strategic growth initiatives, including the FebriDx CLIA waiver trial in the US, advancing product development, driving sales and marketing activities, providing general working capital, and covering costs associated with the Entitlement Offer itself.
2. Who is eligible to participate in the Entitlement Offer?
   

   Shareholders who are eligible to participate in the Entitlement Offer (Eligible Retail Shareholders) are shareholders who:

   • are registered as a holder of Shares in the Company as at 7.00pm (AEST) on the Record Date; and
   • have a registered address on the Company's share register that is in Australia;
   • who are not in the US nor acting for the account or benefit of a person in the US or else outside Australia;
   • do not hold Shares on behalf of another person who reside outside Australia (unless they hold Shares in another eligible capacity); and
   • were not invited to participate in the Institutional Entitlement Offer or treated as an ineligible institutional shareholder for that purpose. Any Retail Shareholders who are not Eligible Retail Shareholders are Ineligible Retail Shareholders.

   The Company reserves the right to determine whether a Shareholder is an Eligible Retail Shareholder or an Ineligible Retail Shareholder.

3. Who do I contact if I haven't received my paperwork yet
   For further information on the Entitlement Offer, if you have questions on how to complete the Entitlement and Acceptance Form, or have lost your Entitlement and Acceptance Form and would like a replacement form, you may contact the Lumos Diagnostics Company Secretary on +61 3 9087 1598 between 9:00am and 5:00pm (AEST) during Monday to Friday, or by e-mail cosec@lumosdiagnostics.com.
4. Who do I contact if I have questions?
   For further information on the Entitlement Offer, if you have questions on how to complete the Entitlement and Acceptance Form, or have lost your Entitlement and Acceptance Form and would like a replacement form, you may contact the Lumos Diagnostics Company Secretary on +61 3 9087 1598 between 9:00am and 5:00pm (AEST) during Monday to Friday, or by e-mail cosec@lumosdiagnostics.com.

Documents

• Retail Entitlement Offer Booklet
• Lumos Announces Intention to Undertake Entitlement Offer
• Lumos Announces $10m Equity Raising and Welcomes Tenmile
• Lumos Successfully Completes Institutional Component of Entitlement Offer
• Retail Entitlement Opens
• Letter to Ineligible Shareholders
• Notice to Eligible Shareholders